Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00373620
Status:
UNKNOWN
Last Update Posted:
2006-09-08
First Post:
2006-09-06
Brief Title:
A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients
Sponsor:
Korean Gynecologic Oncology Group
Organization:
Korean Gynecologic Oncology Group
Study Overview
Official Title:
A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy in High-Risk Endometrial Cancer Patients After Operation
Status:
UNKNOWN
Status Verified Date:
2005-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel is effective and safe in the treatment of high risk postoperative endometrial cancer patients
Detailed Description:
Postoperative radiotherapy RT is the most used adjuvant treatment in high risk endometrial cancer HREC and it appears to reduce the incidence of pelvic relapses but doesnt seem to improve survival Paclitaxel P has shown in vitro and clinical activity against endometrial cancer and it is also a potent radiosensitizer by blocking dividing cells in G2M phase This study is to evaluate the efficacy and safety of a treatment with concomitant weekly chemotherapy with paclitaxel and RT in high risk advanced endometrial cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None